Chemical: Drug

valproic acid

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for valproic acid

	Gene ?	Variant? (147)	Alternate Names ?	Chemicals ?	Alleles ? (+ chr strand)	Function ?	Amino Acid? Translation
VA	CYP2A6	*1A		valproic acid	N/A	N/A	N/A
VIP VA	CYP2A6	*4A		caffeine coumarin efavirenz letrozole nicotine pilocarpine tegafur valproic acid	N/A	N/A	N/A
CA VA	CYP2C19	*1		valproic acid	N/A	N/A	N/A
CA VA	CYP2C19	*2		valproic acid	N/A	N/A	N/A
CA VA	CYP2C19	*3		valproic acid	N/A	N/A	N/A
VA	CYP2C19	*17		valproic acid	N/A	N/A	N/A
CA VA	CYP2C9	*1		valproic acid	N/A	N/A	N/A
CA VA	CYP2C9	*2		valproic acid	N/A	N/A	N/A
CA VA	CYP2C9	*3		valproic acid	N/A	N/A	N/A
VA	GSTM1	non-null		valproic acid	N/A	N/A	N/A
VA	GSTM1	null		valproic acid	N/A	N/A	N/A
VA	GSTT1	non-null		valproic acid	N/A	N/A	N/A
VA	GSTT1	null		valproic acid	N/A	N/A	N/A
VA	HLA-B	*15:02:01		lamotrigine valproic acid	N/A	N/A	N/A
CA VA	UGT1A6	*1a		valproic acid	N/A	N/A	N/A
CA VA	UGT1A6	*2a		valproic acid	N/A	N/A	N/A
CA VA	UGT1A6	*3a		valproic acid	N/A	N/A	N/A
CA VA	UGT1A6	*4a		valproic acid	N/A	N/A	N/A
CA VA	UGT1A6	*8		valproic acid	N/A	N/A	N/A
VA	GABRA1	rs10068980	NC_000005.10:g.161860841G>A, NC_000005.9:g.161287847G>A, NG_011548.1:g.18651G>A, NM_000806.5:c.188-4880G>A, NM_001127643.1:c.188-4880G>A, NM_001127644.1:c.188-4880G>A, NM_001127645.1:c.188-4880G>A, NM_001127648.1:c.188-4880G>A, rs61304955	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	G > A	SNP
CA VA	GRIN2B	rs1019385	NC_000012.11:g.14134843C>A, NC_000012.12:g.13981909C>A, NG_031854.1:g.3180G>T, NM_000834.3:c.-2000G>T, XM_011520628.1:c.-1015G>T, XM_011520629.1:c.-683+7G>T, XM_011520630.1:c.-1632G>T, rs3764029	valproic acid	C > A	SNP
VA	ABCB1	rs1045642	NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664	phenobarbital valproic acid carbamazepine phenytoin	A > G	SNP	I1145I
VA	CPS1	rs1047891	NC_000002.11:g.211540507C>A, NC_000002.12:g.210675783C>A, NG_008285.1:g.203099C>A, NM_001122633.2:c.4235C>A, NM_001122634.3:c.2864C>A, NM_001875.4:c.4217C>A, NP_001116105.1:p.Thr1412Asn, NP_001116106.1:p.Thr955Asn, NP_001866.2:p.Thr1406Asn, XM_005246322.1:c.4250C>A, XM_011510640.1:c.4250C>A, XM_011510641.1:c.4217C>A, XM_011510642.1:c.4217C>A, XM_011510643.1:c.4217C>A, XM_011510644.1:c.4217C>A, XP_005246379.1:p.Thr1417Asn, XP_011508942.1:p.Thr1417Asn, XP_011508943.1:p.Thr1406Asn, XP_011508944.1:p.Thr1406Asn, XP_011508945.1:p.Thr1406Asn, XP_011508946.1:p.Thr1406Asn, rs2229587, rs3187890, rs52831019, rs7422339	valproic acid antiepileptics	C > A	SNP	T1412N
VA	CYP2C9	rs1057910	NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474	valproic acid	A > C	SNP	I359L
VA	CYP2D6	rs1065852	NC_000022.10:g.42526694G=, NC_000022.10:g.42526694G>A, NC_000022.11:g.42130692G=, NC_000022.11:g.42130692G>A, NG_008376.3:g.4300C=, NG_008376.3:g.4300C>T, NM_000106.5:c.100C=, NM_000106.5:c.100C>T, NM_001025161.2:c.100C=, NM_001025161.2:c.100C>T, NP_000097.3:p.Pro34=, NP_000097.3:p.Pro34Ser, NP_001020332.2:p.Pro34=, NP_001020332.2:p.Pro34Ser, NT_187682.1:g.53033G=, NT_187682.1:g.53033G>A, NW_004504305.1:g.53019A=, NW_004504305.1:g.53019A>G, NW_009646208.1:g.16258A=, NW_009646208.1:g.16258A>G, XM_005278353.1:c.100T=, XM_005278353.1:c.100T>C, XM_005278354.1:c.-1454C>T, XM_005278354.1:c.-1454T>C, XM_005278354.3:c.-1454C>T, XM_005278354.3:c.-1454T>C, XM_011529966.1:c.100C=, XM_011529966.1:c.100C>T, XM_011529967.1:c.100C=, XM_011529967.1:c.100C>T, XM_011529968.1:c.100C=, XM_011529968.1:c.100C>T, XM_011529969.1:c.37+605C>T, XM_011529969.1:c.37+605T>C, XM_011529970.1:c.100C=, XM_011529970.1:c.100C>T, XM_011529971.1:c.37+605C>T, XM_011529971.1:c.37+605T>C, XM_011529972.1:c.100C=, XM_011529972.1:c.100C>T, XM_011547541.1:c.-1454C>T, XM_011547541.1:c.-1454T>C, XM_011547750.1:c.37+605C>T, XM_011547750.1:c.37+605T>C, XM_011547751.1:c.-1114C>T, XM_011547751.1:c.-1114T>C, XM_011547756.1:c.42+469A>G, XM_011547756.1:c.42+469G>A, XM_011548819.1:c.-1454C>T, XM_011548819.1:c.-1454T>C, XP_005278410.1:p.Ser34=, XP_005278410.1:p.Ser34Pro, XP_011528268.1:p.Pro34=, XP_011528268.1:p.Pro34Ser, XP_011528269.1:p.Pro34=, XP_011528269.1:p.Pro34Ser, XP_011528270.1:p.Pro34=, XP_011528270.1:p.Pro34Ser, XP_011528272.1:p.Pro34=, XP_011528272.1:p.Pro34Ser, XP_011528274.1:p.Pro34=, XP_011528274.1:p.Pro34Ser, XR_430455.2:n.328+4A>G, XR_430455.2:n.328+4G>A, XR_952536.1:n.-1751A>G, XR_952536.1:n.-1751G>A, XR_952537.1:n.-1751A>G, XR_952537.1:n.-1751G>A, XR_952538.1:n.-1751A>G, XR_952538.1:n.-1751G>A, XR_952539.1:n.-1462A>G, XR_952539.1:n.-1462G>A, XR_952745.1:n.1257C=, XR_952745.1:n.1257C>T, rs117813846, rs58862176	lamotrigine valproic acid primidone carbamazepine phenytoin	G > A	SNP	P34S
VA	PRKAA2	rs10789038	NC_000001.10:g.57117117A>G, NC_000001.11:g.56651444A>G, NM_006252.3:c.94+5963A>G	valproic acid	A > G	SNP
CA VA	UGT1A6	rs1105879	NC_000002.11:g.234602202A>C, NC_000002.12:g.233693556A>C, NG_002601.2:g.108813A>C, NM_001072.3:c.552A>C, NM_019075.2:c.855+56179A>C, NM_019076.4:c.856-73478A>C, NM_019077.2:c.855+10764A>C, NM_021027.2:c.855+20767A>C, NM_205862.1:c.-7-243A>C, NP_001063.2:p.Arg184Ser, XR_241240.1:n.713A>C, XR_241241.1:n.941+20767A>C, rs17684024, rs386516515, rs4365457, rs61226878	valproic acid	A > C	SNP	R184S
VA	GABRA3	rs1112122	NC_000023.10:g.151606004G>T, NC_000023.11:g.152437532G>T, NG_007102.1:g.18827C>A, NM_000808.3:c.-27+13614C>A, XM_005274659.1:c.-27+13614C>A, XM_005274660.1:c.-27+13614C>A, XM_006724811.1:c.-27+13614C>A, XM_011531133.1:c.-27+13614C>A, XM_011531134.1:c.-27+13614C>A, rs60180048	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	G > T	SNP
VA	ABCB1	rs1128503	NC_000007.13:g.87179601A>G, NC_000007.14:g.87550285A>G, NG_011513.1:g.167964T>C, NM_000927.4:c.1236T>C, NP_000918.2:p.Gly412=, rs116989428, rs17276907, rs2032587, rs2229105, rs28365046, rs386518005, rs58257317	phenobarbital valproic acid carbamazepine phenytoin	A > G	SNP	G412G
CA VA	LEPR	rs1137101	NC_000001.10:g.66058513A>G, NC_000001.11:g.65592830A>G, NG_015831.2:g.177266A>G, NM_001003679.3:c.668A>G, NM_001003680.3:c.668A>G, NM_001198687.1:c.668A>G, NM_001198688.1:c.668A>G, NM_001198689.1:c.668A>G, NM_002303.5:c.668A>G, NP_001003679.1:p.Gln223Arg, NP_001003680.1:p.Gln223Arg, NP_001185616.1:p.Gln223Arg, NP_001185617.1:p.Gln223Arg, NP_001185618.1:p.Gln223Arg, NP_002294.2:p.Gln223Arg, XM_005270950.1:c.668A>G, XM_005270951.1:c.668A>G, XM_005270952.1:c.668A>G, XP_005271007.1:p.Gln223Arg, XP_005271008.1:p.Gln223Arg, XP_005271009.1:p.Gln223Arg, rs12131454, rs17356624, rs1805093, rs2229418, rs3200842, rs52820808, rs59347832, rs9282885	valproic acid	A > G	SNP	Q223R
VA	GABRA1	rs1157122	NC_000005.10:g.161892308T>C, NC_000005.9:g.161319314T>C, NG_011548.1:g.50118T>C, NM_000806.5:c.856+1258T>C, NM_001127643.1:c.856+1258T>C, NM_001127644.1:c.856+1258T>C, NM_001127645.1:c.856+1258T>C, NM_001127648.1:c.856+1258T>C, rs57694082	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	T > C	SNP
VA	NTRK2	rs1565445	NC_000009.11:g.87617071G>A, NC_000009.12:g.85002156G>A, NG_012201.2:g.338606G>A, NM_001018064.2:c.2125-18050G>A, NM_006180.4:c.2173-18050G>A, XM_005252001.1:c.2173-18050G>A, XM_005252002.1:c.2173-18050G>A, XM_005252003.1:c.2173-18050G>A, XM_005252004.1:c.2173-18050G>A, XM_005252005.1:c.2125-18050G>A, XM_011518718.1:c.2125-18050G>A, XM_011518719.1:c.2125-18050G>A, rs57679670	lithium valproic acid	G > A	SNP
CA VA	SCN2A	rs17183814	NC_000002.11:g.166152389G>A, NC_000002.12:g.165295879G>A, NG_008143.1:g.61478G>A, NM_001040142.1:c.56G>A, NM_001040143.1:c.56G>A, NM_021007.2:c.56G>A, NP_001035232.1:p.Arg19Lys, NP_001035233.1:p.Arg19Lys, NP_066287.2:p.Arg19Lys, XM_005246750.1:c.56G>A, XM_005246750.2:c.56G>A, XM_005246751.1:c.56G>A, XM_005246752.1:c.56G>A, XM_005246753.1:c.56G>A, XM_005246753.2:c.56G>A, XM_005246754.1:c.27-1G>A, XM_005246754.3:c.27-1G>A, XM_011511608.1:c.56G>A, XM_011511609.1:c.56G>A, XP_005246807.1:p.Arg19Lys, XP_005246808.1:p.Arg19Lys, XP_005246809.1:p.Arg19Lys, XP_005246810.1:p.Arg19Lys, XP_011509910.1:p.Arg19Lys, XP_011509911.1:p.Arg19Lys, rs52803852	phenobarbital antiepileptics valproic acid carbamazepine phenytoin	G > A	SNP	R19K
VA	ABAT	rs1731017		valproic acid	A > G	SNP	Q56R
VA	CYP2C9	rs1799853	NC_000010.10:g.96702047C=, NC_000010.10:g.96702047C>T, NC_000010.11:g.94942290C=, NC_000010.11:g.94942290C>T, NG_008385.1:g.8633C=, NG_008385.1:g.8633C>T, NM_000771.3:c.430C=, NM_000771.3:c.430C>T, NP_000762.2:p.Arg144=, NP_000762.2:p.Arg144Cys, XM_005269575.1:c.430C=, XM_005269575.1:c.430C>T, XP_005269632.1:p.Arg144=, XP_005269632.1:p.Arg144Cys, rs17110268, rs28371674, rs33968134, rs60690363	valproic acid	C > T	SNP	R144C
VA	FABP2	rs1799883	NC_000004.11:g.120241902T>C, NC_000004.12:g.119320747T>C, NG_011444.1:g.6415A>G, NM_000134.3:c.163A>G, NP_000125.2:p.Thr55Ala, rs117220903, rs17694079, rs52836284	valproic acid	T > C	SNP	T55A
CA VA	COL1A1	rs1800012	NC_000017.10:g.48277749C=, NC_000017.10:g.48277749C>A, NC_000017.11:g.50200388C=, NC_000017.11:g.50200388C>A, NG_007400.1:g.6252G=, NG_007400.1:g.6252G>T, NM_000088.3:c.104-441G=, NM_000088.3:c.104-441G>T, XM_005257058.1:c.104-441G=, XM_005257058.1:c.104-441G>T, XM_005257058.3:c.104-441G=, XM_005257058.3:c.104-441G>T, XM_005257059.1:c.104-441G=, XM_005257059.1:c.104-441G>T, XM_005257059.3:c.104-441G=, XM_005257059.3:c.104-441G>T, XM_011524341.1:c.104-441G=, XM_011524341.1:c.104-441G>T, rs58312232, rs8179177	valproic acid	C > A	SNP
CA VA	ANKK1	rs1800497	NC_000011.10:g.113400106G>A, NC_000011.9:g.113270828G>A, NG_012976.1:g.17316G>A, NM_178510.1:c.2137G>A, NP_848605.1:p.Glu713Lys, XM_011542736.1:c.2170G>A, XM_011542737.1:c.2140G>A, XM_011542738.1:c.1948G>A, XP_011541038.1:p.Glu724Lys, XP_011541039.1:p.Glu714Lys, XP_011541040.1:p.Glu650Lys, rs117686243, rs4134623, rs4245144, rs59538675	valproic acid	G > A	SNP	E713K
CA VA	ABCB1	rs2032582	NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018	phenobarbital valproic acid carbamazepine phenytoin	A > C A > T	SNP	S893A
CA VA	UGT1A10 UGT1A6 UGT1A7 UGT1A8 UGT1A9	rs2070959	NC_000002.11:g.234602191A>G, NC_000002.12:g.233693545A>G, NG_002601.2:g.108802A>G, NM_001072.3:c.541A>G, NM_019075.2:c.855+56168A>G, NM_019076.4:c.856-73489A>G, NM_019077.2:c.855+10753A>G, NM_021027.2:c.855+20756A>G, NM_205862.1:c.-7-254A>G, NP_001063.2:p.Thr181Ala, XR_241240.1:n.702A>G, XR_241241.1:n.941+20756A>G, rs17683988, rs386556316, rs3903007, rs61246460	valproic acid	A > G	SNP	T181A
VA	GABRG2	rs211037	NC_000005.10:g.162101274C>T, NC_000005.9:g.161528280C>T, NG_009290.1:g.38633C>T, NM_000816.3:c.588C>T, NM_198903.2:c.588C>T, NM_198904.2:c.588C>T, NP_000807.2:p.Asn196=, NP_944493.2:p.Asn196=, NP_944494.1:p.Asn196=, XM_005265870.1:c.588C>T, XP_005265927.1:p.Asn196=, rs3765200, rs61071827	phenobarbital valproic acid carbamazepine phenytoin	C > T	SNP	N196N
VA	GABRB2	rs2229944	NC_000005.10:g.161294312G>A, NC_000005.9:g.160721319G>A, NM_000813.2:c.1194C>T, NM_021911.2:c.1308C>T, NP_000804.1:p.Ala398=, NP_068711.1:p.Ala436=, XM_005265867.1:c.1308C>T, XM_005265868.1:c.1194C>T, XM_005265869.1:c.1200C>T, XM_011534501.1:c.558C>T, XP_005265924.1:p.Ala436=, XP_005265925.1:p.Ala398=, XP_005265926.1:p.Ala400=, XP_011532803.1:p.Ala186=, rs118051818, rs386561760	phenobarbital valproic acid carbamazepine phenytoin	G > A	SNP	A398A
VA	XBP1	rs2269577	NC_000022.10:g.29196757G>C, NC_000022.11:g.28800769G>C, NG_012266.1:g.4804C>G, NM_001079539.1:c.-245C>G, NM_005080.3:c.-245C>G, XM_011530435.1:c.-194+32G>C, XM_011530436.1:c.-262+32G>C, rs61323997	valproic acid	G > C	SNP
CA VA	GABRA1	rs2279020	NC_000005.10:g.161895883G>A, NC_000005.9:g.161322889G>A, NG_011548.1:g.53693G>A, NM_000806.5:c.1059+15G>A, NM_001127643.1:c.1059+15G>A, NM_001127644.1:c.1059+15G>A, NM_001127645.1:c.1059+15G>A, NM_001127648.1:c.1059+15G>A	phenobarbital valproic acid carbamazepine phenytoin	G > A	SNP
VA	SCN1A	rs2298771	AB093548.1:c.3199A=, AB093548.1:c.3199A>G, BAC21101.1:p.Thr1067=, BAC21101.1:p.Thr1067Ala, NC_000002.11:g.166892788C>T, NC_000002.12:g.166036278C>T, NG_011906.1:g.42362G>A, NM_001165963.1:c.3199G>A, NM_001165964.1:c.3115G>A, NM_001202435.1:c.3199G>A, NM_006920.4:c.3166G>A, NP_001159435.1:p.Ala1067Thr, NP_001159436.1:p.Ala1039Thr, NP_001189364.1:p.Ala1067Thr, NP_008851.3:p.Ala1056Thr, NR_110598.1:n.618C>T, XM_011511598.1:c.3199G>A, XM_011511599.1:c.3199G>A, XM_011511600.1:c.3199G>A, XM_011511601.1:c.3199G>A, XM_011511602.1:c.3199G>A, XM_011511603.1:c.3196G>A, XM_011511604.1:c.3166G>A, XM_011511605.1:c.3163G>A, XM_011511606.1:c.3115G>A, XM_011511607.1:c.3199G>A, XP_011509900.1:p.Ala1067Thr, XP_011509901.1:p.Ala1067Thr, XP_011509902.1:p.Ala1067Thr, XP_011509903.1:p.Ala1067Thr, XP_011509904.1:p.Ala1067Thr, XP_011509905.1:p.Ala1066Thr, XP_011509906.1:p.Ala1056Thr, XP_011509907.1:p.Ala1055Thr, XP_011509908.1:p.Ala1039Thr, XP_011509909.1:p.Ala1067Thr, XR_922981.1:n.3383G>A, rs17736325, rs52795097, rs57078271	valproic acid carbamazepine phenytoin	C > - C > A	SNP	A1067T
VA	POLG	rs2307441	NC_000015.10:g.89318595T>C, NC_000015.9:g.89861826T>C, NG_008218.1:g.21201A>G, NG_011736.1:g.79633T>C, NM_001126131.1:c.3428A>G, NM_002693.2:c.3428A>G, NP_001119603.1:p.Glu1143Gly, NP_002684.1:p.Glu1143Gly, rs17804944, rs3176226	valproic acid	T > C	SNP	E1143G
CA VA	CYP1A1	rs2606345	NC_000015.10:g.74724835C>A, NC_000015.9:g.75017176C>A, NG_008431.1:g.7294C>A, NM_000499.3:c.-27+606G>T, NM_000499.4:c.-27+606G>T, NM_001319216.1:c.-30+606G>T, NM_001319217.1:c.-30+606G>T, XM_005254185.1:c.-30+606G>T, XM_005254186.1:c.-30+330G>T, XM_005254187.1:c.-30+606G>T, XM_005254188.1:c.-30+606G>T, XM_005254189.1:c.-221+606G>T, rs17861098	phenobarbital valproic acid carbamazepine phenytoin	C > A	SNP
VA	CYP3A4	rs2687116	NC_000007.13:g.99365943C>A, NC_000007.14:g.99768320C>A, NG_008421.1:g.20866G>T, NM_001202855.2:c.670+34G>T, NM_017460.5:c.670+34G>T, XM_011515841.1:c.670+34G>T, XM_011515842.1:c.670+34G>T, rs17161901, rs59381366	lamotrigine valproic acid primidone carbamazepine phenytoin	C > A	SNP
VA	CYP3A4	rs2740574	NC_000007.13:g.99382096C>T, NC_000007.14:g.99784473C>T, NG_008421.1:g.4713G>A, NM_001202855.2:c.-392G>A, NM_017460.5:c.-392G>A, XM_011515841.1:c.-392G>A, XM_011515842.1:c.-392G>A, rs3176920, rs36231114, rs59393892	lamotrigine valproic acid primidone carbamazepine phenytoin	C > T	SNP
VA	UGT1A10 UGT1A7 UGT1A8 UGT1A9	rs2741049	NC_000002.11:g.234581834T>C, NC_000002.12:g.233673188T>C, NG_002601.2:g.88445T>C, NM_019075.2:c.855+35811T>C, NM_019076.4:c.855+54626T>C, NM_021027.2:c.855+399T>C, XR_241241.1:n.941+399T>C, rs17863541, rs58960856	valproic acid	T > C	SNP
CA VA		rs2769605	NC_000009.11:g.87912671C>T, NC_000009.12:g.85297756C>T, rs60079633, rs61163227	lithium valproic acid	C > T	SNP
VA	UGT2B7	rs28365062	NC_000004.11:g.69964271A>G, NC_000004.12:g.69098553A>G, NM_001074.2:c.735A>G, NP_001065.2:p.Thr245=, XM_005265702.1:c.-13A>G, XM_005265702.2:c.-13A>G, XM_011532229.1:c.735A>G, XM_011532230.1:c.735A>G, XM_011532231.1:c.-13A>G, XP_011530531.1:p.Thr245=, XP_011530532.1:p.Thr245=, rs58136729	valproic acid	A > G	SNP	T245T
CA VA	POLG	rs3087374	NC_000015.10:g.89316763C>A, NC_000015.9:g.89859994C>A, NG_008218.1:g.23033G>T, NG_011736.1:g.77801C>A, NM_001113378.1:c.*304C>A, NM_001126131.1:c.3708G>T, NM_002693.2:c.3708G>T, NM_018193.2:c.*304C>A, NP_001119603.1:p.Gln1236His, NP_002684.1:p.Gln1236His, XM_005254946.1:c.*304C>A, XM_005254947.1:c.*304C>A, XM_005254948.1:c.*304C>A, XM_005254949.1:c.*304C>A, XM_005254950.1:c.*304C>A, XM_005254951.1:c.*304C>A, XM_005254952.1:c.*304C>A, XM_005254953.1:c.*304C>A, XM_011521756.1:c.*304C>A, XM_011521757.1:c.*304C>A, XM_011521758.1:c.*304C>A, XM_011521759.1:c.*304C>A, XM_011521760.1:c.*304C>A, XM_011521761.1:c.*304C>A, XM_011521762.1:c.*304C>A, XM_011521763.1:c.*304C>A, XM_011521764.1:c.*304C>A, XM_011521765.1:c.*304C>A, XM_011521766.1:c.*304C>A, XM_011521767.1:c.*304C>A, XM_011521769.1:c.*304C>A, XR_243211.1:n.4144C>A, XR_243212.1:n.3964C>A, rs17804776, rs3176244, rs386579081, rs61472028	valproic acid	C > A C > T	SNP	Q1236H
VA	GABRA6	rs3219151	NC_000005.10:g.161701908C>T, NC_000005.9:g.161128914C>T, NM_000811.2:c.*135C>T, rs17059674, rs57122315	phenobarbital valproic acid carbamazepine phenytoin	C > T	SNP
VA	SCN1A	rs3812718	AB093548.1:c.603-91G>A, NC_000002.11:g.166909544C>T, NC_000002.12:g.166053034C>T, NG_011906.1:g.25606G>A, NM_001165963.1:c.603-91G>A, NM_001165964.1:c.603-91G>A, NM_001202435.1:c.603-91G>A, NM_006920.4:c.603-91G>A, XM_011511598.1:c.603-91G>A, XM_011511599.1:c.603-91G>A, XM_011511600.1:c.603-91G>A, XM_011511601.1:c.603-91G>A, XM_011511602.1:c.603-91G>A, XM_011511603.1:c.603-91G>A, XM_011511604.1:c.603-91G>A, XM_011511605.1:c.603-91G>A, XM_011511606.1:c.603-91G>A, XM_011511607.1:c.603-91G>A, XR_922981.1:n.787-91G>A, rs57229005	valproic acid carbamazepine	C > T	SNP
VA	APEH	rs3816877		valproic acid	C > T	SNP	T541M
VA	CYP2D6	rs3892097	NC_000022.10:g.42524947C=, NC_000022.10:g.42524947C>T, NC_000022.11:g.42128945C=, NC_000022.11:g.42128945C>T, NG_008376.3:g.6047G=, NG_008376.3:g.6047G>A, NM_000106.5:c.506-1A>G, NM_000106.5:c.506-1G>A, NM_001025161.2:c.353-1A>G, NM_001025161.2:c.353-1G>A, NT_187682.1:g.51286C=, NT_187682.1:g.51286C>T, NW_004504305.1:g.51272T=, NW_004504305.1:g.51272T>C, NW_009646208.1:g.14511C=, NW_009646208.1:g.14511C>T, XM_005278353.1:c.363-2A>G, XM_005278353.1:c.363-2G>A, XM_005278354.1:c.207-2A>G, XM_005278354.1:c.207-2G>A, XM_005278354.3:c.207-2A>G, XM_005278354.3:c.207-2G>A, XM_011529966.1:c.506-1A>G, XM_011529966.1:c.506-1G>A, XM_011529967.1:c.506-1A>G, XM_011529967.1:c.506-1G>A, XM_011529968.1:c.506-1A>G, XM_011529968.1:c.506-1G>A, XM_011529969.1:c.363-2A>G, XM_011529969.1:c.363-2G>A, XM_011529970.1:c.353-1A>G, XM_011529970.1:c.353-1G>A, XM_011529971.1:c.363-2A>G, XM_011529971.1:c.363-2G>A, XM_011529972.1:c.506-1A>G, XM_011529972.1:c.506-1G>A, XM_011547541.1:c.207-2A>G, XM_011547541.1:c.207-2G>A, XM_011547750.1:c.363-2A>G, XM_011547750.1:c.363-2G>A, XM_011547751.1:c.290-1A>G, XM_011547751.1:c.290-1G>A, XM_011547756.1:c.-1090C>T, XM_011547756.1:c.-1090T>C, XM_011548819.1:c.207-2A>G, XM_011548819.1:c.207-2G>A, XR_430455.2:n.-926C>T, XR_430455.2:n.-926T>C, XR_952745.1:n.1663-1A>G, XR_952745.1:n.1663-1G>A, rs1800716, rs28371711, rs60082401, rs606231227	lamotrigine valproic acid primidone carbamazepine phenytoin	C > T	SNP
VA	CYP2C19	rs4244285	NC_000010.10:g.96541616G>A, NC_000010.11:g.94781859G>A, NG_008384.2:g.24154G>A, NM_000769.1:c.681G>A, NM_000769.2:c.681G>A, NP_000760.1:p.Pro227=, rs116940633, rs17879456, rs60361278	valproic acid	G > A	SNP	P227P
VIP	COMT	rs4680	NC_000022.10:g.19951271G>A, NC_000022.11:g.19963748G>A, NG_011526.1:g.27009G>A, NM_000754.3:c.472G>A, NM_001135161.1:c.472G>A, NM_001135162.1:c.472G>A, NM_007310.2:c.322G>A, NP_000745.1:p.Val158Met, NP_001128633.1:p.Val158Met, NP_001128634.1:p.Val158Met, NP_009294.1:p.Val108Met, NR_039918.1:n.-5G>A, XM_005261229.1:c.472G>A, XM_011529885.1:c.586G>A, XM_011529886.1:c.586G>A, XM_011529887.1:c.472G>A, XM_011529888.1:c.472G>A, XM_011529889.1:c.472G>A, XM_011529890.1:c.472G>A, XM_011529891.1:c.472G>A, XP_005261286.1:p.Val158Met, XP_011528187.1:p.Val196Met, XP_011528188.1:p.Val196Met, XP_011528189.1:p.Val158Met, XP_011528190.1:p.Val158Met, XP_011528191.1:p.Val158Met, XP_011528192.1:p.Val158Met, XP_011528193.1:p.Val158Met, rs1131157, rs11544671, rs165688, rs17295216, rs17349704, rs17818178, rs17849308, rs17850006, rs2070104, rs3177905, rs3190784, rs3747070, rs58002978		G > A	SNP	V158M
VA	GABRA3	rs4828696	NC_000023.10:g.151581996T>C, NC_000023.11:g.152413524T>C, NG_007102.1:g.42835A>G, NM_000808.3:c.-27+37622A>G, XM_005274659.1:c.-27+37622A>G, XM_005274660.1:c.-27+37622A>G, XM_006724811.1:c.-27+37622A>G, XM_011531133.1:c.-27+37622A>G, XM_011531134.1:c.-27+37622A>G, rs56568387, rs60127194	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	T > C	SNP
CA VA	SOD2	rs4880	NC_000006.11:g.160113872A>G, NC_000006.12:g.159692840A>G, NG_008729.1:g.5482T>C, NM_000636.2:c.47T>C, NM_001024465.1:c.47T>C, NM_001024466.1:c.47T>C, NP_000627.2:p.Val16Ala, NP_001019636.1:p.Val16Ala, NP_001019637.1:p.Val16Ala, rs1141717, rs11551083, rs116851270, rs17362379, rs17405198, rs17856520, rs1799725, rs3205539, rs386596107	valproic acid	A > G	SNP	V16A
VA		rs511310	NC_000004.11:g.46240004A>G, NC_000004.12:g.46237987A>G, rs59093609	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	A > G	SNP
VA	UGT1A10 UGT1A7 UGT1A8 UGT1A9	rs6731242	NC_000002.11:g.234578693T>G, NC_000002.12:g.233670047T>G, NG_002601.2:g.85304T>G, NM_019075.2:c.855+32670T>G, NM_019076.4:c.855+51485T>G, NM_021027.2:c.-1888T>G, XR_241241.1:n.-1802T>G	valproic acid	T > A T > G	SNP
CA VA	UGT1A10 UGT1A6 UGT1A7 UGT1A8 UGT1A9	rs6759892	NC_000002.11:g.234601669T>G, NC_000002.12:g.233693023T>G, NG_002601.2:g.108280T>G, NM_001072.3:c.19T>G, NM_019075.2:c.855+55646T>G, NM_019076.4:c.856-74011T>G, NM_019077.2:c.855+10231T>G, NM_021027.2:c.855+20234T>G, NM_205862.1:c.-7-776T>G, NP_001063.2:p.Ser7Ala, XR_241240.1:n.180T>G, XR_241241.1:n.941+20234T>G, rs17670302, rs60624335	valproic acid	T > G	SNP	S7A
VA	GABRA1	rs6883877	NC_000005.10:g.161851332C>T, NC_000005.9:g.161278338C>T, NG_011548.1:g.9142C>T, NM_000806.5:c.74+448C>T, NM_001127643.1:c.74+448C>T, NM_001127644.1:c.74+448C>T, NM_001127645.1:c.74+448C>T, NM_001127648.1:c.74+448C>T, rs56705003	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	C > T	SNP
VA	GABRA1	rs6892782	NC_000005.10:g.161842777T>C, NC_000005.9:g.161269783T>C, NG_011548.1:g.587T>C, rs56770940	lamotrigine oxcarbazepine gabapentin phenytoin topiramate valproic acid carbamazepine	T > C	SNP
VA	UGT2B7	rs7438284	NC_000004.11:g.69964337A>T, NC_000004.12:g.69098619A>T, NM_001074.2:c.801A>T, NP_001065.2:p.Pro267=, XM_005265702.1:c.54A>T, XM_005265702.2:c.54A>T, XM_011532229.1:c.801A>T, XM_011532230.1:c.801A>T, XM_011532231.1:c.54A>T, XP_005265759.1:p.Pro18=, XP_011530531.1:p.Pro267=, XP_011530532.1:p.Pro267=, XP_011530533.1:p.Pro18=, rs58290492	valproic acid lorazepam	A > T	SNP	P267P
CA VA	UGT2B7	rs7439366	NC_000004.11:g.69964338T>C, NC_000004.12:g.69098620T>C, NM_001074.2:c.802T>C, NP_001065.2:p.Tyr268His, XM_005265702.1:c.55T>C, XM_005265702.2:c.55T>C, XM_011532229.1:c.802T>C, XM_011532230.1:c.802T>C, XM_011532231.1:c.55T>C, XP_005265759.1:p.Tyr19His, XP_011530531.1:p.Tyr268His, XP_011530532.1:p.Tyr268His, XP_011530533.1:p.Tyr19His, rs34924067, rs57980137	valproic acid lorazepam	T > C	SNP	Y268H
VA	UGT2B7	rs7668258	NC_000004.11:g.69962078T>C, NC_000004.12:g.69096360T>C, NM_001074.2:c.-161T>C, XM_005265702.1:c.-26-2180T>C, XM_005265702.2:c.-26-2180T>C, XM_011532229.1:c.-161T>C, XM_011532230.1:c.-161T>C, XM_011532231.1:c.-26-2180T>C, rs17551675, rs60174701	valproic acid	T > C	SNP
VA	CYP2C9	rs9332120	NC_000010.10:g.96701850T>C, NC_000010.11:g.94942093T>C, NG_008385.1:g.8436T>C, NM_000771.3:c.331+73T>C, XM_005269575.1:c.331+73T>C	lamotrigine valproic acid primidone carbamazepine phenytoin	T > C	SNP

[ see larger image ] [ see 3D structure ]

provided by PubChem

Overview

PharmGKB Accession Id

PA451846

Type(s):

Drug

Other Vocabularies

• ATC: Fatty acid derivatives (N03AG)
• UMLS: Valproic Acid (C0042291)
• RxNorm: Valproic Acid (11118)
• NDFRT: VALPROIC ACID (N0000147028)

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Absorption, Distribution, Metabolism, Elimination & Toxicity

Chemical Properties

CCCC(CCC)C(=O)O

InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

1. Valproic Acid Pathway, Pharmacodynamics
   Graphic representation of the candidate genes involved in valproic acid pharmacodynamics.

2. Valproic Acid Pathway, Pharmacokinetics
   Graphic representation of the candidate genes involved in valproic acid pharmacokinetics.

Publications related to valproic acid: 88

VA	Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy. Pharmacological reports : PR. 2017. López-García Miguel A, et al.
VA	Polymorphisms of ABAT, SCN2A and ALDH5A1 may affect valproic acid responses in the treatment of epilepsy in Chinese. Pharmacogenomics. 2016. Li Xi, et al.
	Pharmacogenomics and histone deacetylase inhibitors. Pharmacogenomics. 2016. Goey Andrew Kl, et al.
	Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers. Pharmacogenomics. 2016. Fricke-Galindo Ingrid, et al.
CA VA	Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data. European journal of clinical pharmacology. 2016. Smith R L, et al.
VA	Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients. Pharmacogenomics. 2016. Wen Zhi Peng, et al.
CA VA	Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain. Acta neurologica Scandinavica. 2016. Noai M, et al.
CA	Genetic contribution of CYP1A1 variant on treatment outcome in epilepsy patients: a functional and interethnic perspective. The pharmacogenomics journal. 2016. Talwar P, et al.
CA VA	The COL1A1 SP1 polymorphism is associated with lower bone mineral density in patients treated with valproic acid. Pharmacogenetics and genomics. 2015. Villegas-Martínez Irene, et al.
CA VA	Association of LEPR and ANKK1 gene polymorphisms with weight gain in epilepsy patients receiving valproic acid. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2015. Li Hongliang, et al.
VA	Association between HLA-B*15:02 allele and antiepileptic drug-induced severe cutaneous reactions in Hong Kong Chinese: a population-based study. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2014. Kwan P K L, et al.
	Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics. 2014. Gentile Giovanna, et al.
CA	Association of SCN1A, SCN2A and ABCC2 gene polymorphisms with the response to antiepileptic drugs in Chinese Han patients with epilepsy. Pharmacogenomics. 2014. Ma Chun-Lai, et al.
	Use of magnetic resonance imaging in pharmacogenomics. British journal of clinical pharmacology. 2014. Viviani Roberto, et al.
CA VA	Impact of the Superoxide Dismutase 2 Val16Ala Polymorphism on the Relationship between Valproic Acid Exposure and Elevation of gamma-Glutamyltransferase in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis. PloS one. 2014. Ogusu Naoki, et al.
VA	Gene-wide tagging study of the effects of common genetic polymorphisms in the alpha subunits of the GABAA receptor on epilepsy treatment response. Pharmacogenomics. 2013. Hung Chin-Chuan, et al.
VA	GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. Pharmacogenetics and genomics. 2013. Balan Shabeesh, et al.
VA	HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013. Cheung Ying-Kit, et al.
CA VA	SCN1A, SCN2A and SCN3A gene polymorphisms and responsiveness to antiepileptic drugs: a multicenter cohort study and meta-analysis. Pharmacogenomics. 2013. Haerian Batoul Sadat, et al.
	Prospective study of POLG mutations presenting in children with intractable epilepsy: prevalence and clinical features. Epilepsia. 2013. Uusimaa Johanna, et al.
	Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al.
	Pharmacogenomics of bipolar disorder. Pharmacogenomics. 2013. Severino Giovanni, et al.
	Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2013. Ghodke-Puranik Yogita, et al.
CA VA	Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) Gene Associated with Treatment Response to Mood Stabilizers in Patients with Bipolar I Disorder. Journal of molecular neuroscience : MN. 2013. Wang Zuowei, et al.
VIP	PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and genomics. 2012. McDonagh Ellen M, et al.
	Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics. 2012. Hilger Eva, et al.
	A genomic approach to predict synergistic combinations for breast cancer treatment. The pharmacogenomics journal. 2011. Soldi R, et al.
	Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy. The Indian journal of medical research. 2011. Lakhan Ram, et al.
CA VA	Association of genetic variants in six candidate genes with valproic acid therapy optimization. Pharmacogenomics. 2011. Hung Chin-Chuan, et al.
	Effects of valproic acid on organic acid metabolism in children: a metabolic profiling study. Clinical pharmacology and therapeutics. 2011. Price K E, et al.
CA VA	Pharmacogenomic association study on the role of drug metabolizing, drug transporters and drug target gene polymorphisms in drug-resistant epilepsy in a north Indian population. Indian journal of human genetics. 2011. Kumari Ritu, et al.
	Perspectives on Epigenetics and Its Relevance to Adverse Drug Reactions. Clinical pharmacology and therapeutics. 2011. Kacevska M, et al.
	Drug-resistant epilepsia and fulminant valproate liver toxicity. Alpers-Huttenlocher syndrome in two children confirmed post mortem by identification of p.W748S mutation in POLG gene. Medical science monitor : international medical journal of experimental and clinical research. 2011. Pronicka Ewa, et al.
	Pharmacogenetics of drug-induced birth defects: what is known so far?. Pharmacogenomics. 2011. Wilffert Bob, et al.
	POLG1 manifestations in childhood. Neurology. 2011. Isohanni P, et al.
	Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011. Kwan Patrick, et al.
	Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. The pharmacogenomics journal. 2011. Gupta A, et al.
	New insights on the mechanisms of valproate-induced hyperammonemia: Inhibition of hepatic N-acetylglutamate synthase activity by valproyl-Coa. Journal of hepatology. 2010. Aires Cátia C P, et al.
CA VA	Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology (Baltimore, Md.). 2010. Stewart Joanna D, et al.
CA VA	Genetic polymorphisms in sex hormone metabolizing genes and drug response in women with epilepsy. Pharmacogenomics. 2010. Grover Sandeep, et al.
	Identifying genomic and developmental causes of adverse drug reactions in children. Pharmacogenomics. 2010. Becker Mara L, et al.
	Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al.
VA	Effect of CPS14217C>A genotype on valproic-acid-induced hyperammonemia. Pediatrics international : official journal of the Japan Pediatric Society. 2010. Yagi Mariko, et al.
	Transporter hypothesis of drug-resistant epilepsy: challenges for pharmacogenetic approaches. Pharmacogenomics. 2010. Potschka Heidrun.
VA	Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicology mechanisms and methods. 2010. Amini-Shirazi Noushin, et al.
CA VA	Absence of a general association between ABCB1 genetic variants and response to antiepileptic drugs in epilepsy patients. Biochimie. 2010. Grover Sandeep, et al.
	Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment. Pharmacogenomics. 2010. Grover Sandeep, et al.
VA VIP	The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clinical neurology and neurosurgery. 2010. Tan Lan, et al.
	POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure : the journal of the British Epilepsy Association. 2010. Saneto Russell P, et al.
	Key factors in the discovery and development of new antiepileptic drugs. Nature reviews. Drug discovery. 2010. Bialer Meir, et al.
	Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling. European journal of clinical pharmacology. 2009. Jiang Dechun, et al.
	Molecular and therapeutic potential and toxicity of valproic acid. Journal of biomedicine & biotechnology. 2010. Chateauvieux Sébastien, et al.
	Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of hematology & oncology. 2010. Tan Jiahuai, et al.
	Structure, function, regulation and polymorphism of human cytochrome P450 2A6. Current drug metabolism. 2009. Di Yuan Ming, et al.
CA VA	Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. British journal of clinical pharmacology. 2009. Lakhan Ram, et al.
VA	Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Voso Maria Teresa, et al.
VA	Preliminary evidence on the association between XBP1-116C/G polymorphism and response to prophylactic treatment with valproate in bipolar disorders. Psychiatry research. 2009. Kim Byungsu, et al.
	Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Hauswald Stefanie, et al.
	Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia. 2009. Wolf Nicole I, et al.
	Epilepsy pharmacogenetics. Pharmacogenomics. 2009. Kasperavici¿te Dalia, et al.
	Gene-wide tagging study of association between ABCB1 polymorphisms and multidrug resistance in epilepsy in Han Chinese. Pharmacogenomics. 2009. Kwan Patrick, et al.
	Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Molecular biology reports. 2009. Turgut Gunfer, et al.
CA VA	No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population. Epilepsy & behavior : E&B. 2009. Lakhan R, et al.
	Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). BMJ case reports. 2009. McFarland R, et al.
	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al.
	Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenetics and genomics. 2008. Tabolacci Elisabetta, et al.
	Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al.
	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenetics and genomics. 2008. Hung Chin-Chuan, et al.
CA VA	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clinical pharmacology and therapeutics. 2008. Chung J-Y, et al.
	Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase gamma (POLG1). Archives of disease in childhood. 2008. McFarland R, et al.
VIP	Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug metabolism and disposition: the biological fate of chemicals. 2007. Cerveny Lukas, et al.
	Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic & clinical pharmacology & toxicology. 2007. Gunes Arzu, et al.
	Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicological sciences : an official journal of the Society of Toxicology. 2006. Kiang Tony K L, et al.
	Mitochondrial DNA polymerase-gamma and human disease. Human molecular genetics. 2006. Hudson Gavin, et al.
	In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of neurology. 2006. Brichta Lars, et al.
	ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006. Seo Takayuki, et al.
	Defining the clinical role of pharmacogenetics in antiepileptic drug therapy. The pharmacogenomics journal. 2006. Dlugos D J, et al.
	Idiosyncratic drug hepatotoxicity. Nature reviews. Drug discovery. 2005. Kaplowitz Neil.
CA VA	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). The Journal of pharmacology and experimental therapeutics. 2005. Krishnaswamy Soundararajan, et al.
	The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases. Biochemical pharmacology. 2003. Ethell Brian T, et al.
VA	Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. The pharmacogenomics journal. 2003. Ho P C, et al.
	Med-psych drug-drug interactions update. Psychosomatics. 2002. Armstrong Scott C, et al.
	In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). British journal of clinical pharmacology. 2001. Wen X, et al.
	Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. The Journal of pharmacology and experimental therapeutics. 1997. Sadeque A J, et al.
VIP	Effect of valproate on the pharmacokinetics and pharmacodynamics of lorazepam. Journal of clinical pharmacology. 1997. Samara E E, et al.
VIP	Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997. Rosenfeld W E, et al.
	Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase?. Therapeutic drug monitoring. 1995. Svinarov D A, et al.
	The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. Biochimica et biophysica acta. 1990. Ito M, et al.

LinkOuts